Nutra Pharma Statistics
Total Valuation
Nutra Pharma has a market cap or net worth of 1.43 million. The enterprise value is 12.62 million.
| Market Cap | 1.43M |
| Enterprise Value | 12.62M |
Important Dates
The next estimated earnings date is Wednesday, April 22, 2026.
| Earnings Date | Apr 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutra Pharma has 7.16 billion shares outstanding. The number of shares has increased by 1.29% in one year.
| Current Share Class | 7.16B |
| Shares Outstanding | 7.16B |
| Shares Change (YoY) | +1.29% |
| Shares Change (QoQ) | -79.28% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 0.00% |
| Float | 7.09B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.16 |
| PB Ratio | -0.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.05 |
| EV / Sales | 27.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.99 |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -9.75 |
| Interest Coverage | -3.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -115.80% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7.25% |
| Weighted Average Cost of Capital (WACC) | 44.48% |
| Revenue Per Employee | 75,462 |
| Profits Per Employee | -298,296 |
| Employee Count | 6 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 9.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 66.62, so Nutra Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 66.62 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 59.88 |
| Average Volume (20 Days) | 354,059 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Nutra Pharma had revenue of 452,771 and -1.79 million in losses. Loss per share was -0.00.
| Revenue | 452,771 |
| Gross Profit | 295,123 |
| Operating Income | -1.18M |
| Pretax Income | -1.79M |
| Net Income | -1.79M |
| EBITDA | -1.17M |
| EBIT | -1.18M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 21,203 in cash and 11.19 million in debt, with a net cash position of -11.17 million or -0.00 per share.
| Cash & Cash Equivalents | 21,203 |
| Total Debt | 11.19M |
| Net Cash | -11.17M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -16.35M |
| Book Value Per Share | -0.00 |
| Working Capital | -16.38M |
Cash Flow
In the last 12 months, operating cash flow was -1.12 million and capital expenditures -26,052, giving a free cash flow of -1.15 million.
| Operating Cash Flow | -1.12M |
| Capital Expenditures | -26,052 |
| Depreciation & Amortization | 9,937 |
| Net Borrowing | 1.17M |
| Free Cash Flow | -1.15M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 65.18% |
| Operating Margin | -259.58% |
| Pretax Margin | -395.29% |
| Profit Margin | n/a |
| EBITDA Margin | -257.38% |
| EBIT Margin | -259.58% |
| FCF Margin | n/a |
Dividends & Yields
Nutra Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.29% |
| Shareholder Yield | -1.29% |
| Earnings Yield | -124.99% |
| FCF Yield | -80.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 18, 2015. It was a reverse split with a ratio of 0.025.
| Last Split Date | May 18, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Nutra Pharma has an Altman Z-Score of -185.9 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -185.9 |
| Piotroski F-Score | 5 |